The 10mg semaglutide dosage chart, and the misconception behind it

The biggest myth: that 10mg is a standard Wegovy rung

Search for semaglutide dosage information and you will find references to doses that simply do not match the UK-licensed product, as our 10 mg semaglutide dosage chart page explains in full. The 10mg figure crops up most often in two contexts: compounded semaglutide made outside the licensed supply chain, and overseas or US-focused content that has migrated into UK search results. Neither is relevant to someone seeking regulated treatment in Britain.

Wegovy, as authorised by the MHRA, works on a fixed escalation: 0.25mg for the first four weeks, then 0.5mg, 1.0mg, 1.7mg, and 2.4mg as the original maintenance dose. In April 2026 the MHRA approved a dedicated 7.2mg single-dose pen, raising the ceiling for adults with a BMI of 30 or above who need a higher maintenance dose. That is the complete licensed picture. There is no 10mg step, and no legitimate UK pharmacy dispenses one. If a website is selling 10mg semaglutide as a weight-loss treatment, that is a serious red flag, the MHRA has warned repeatedly about unlicensed and counterfeit GLP-1 products circulating online. You can report suspect sellers at the MHRA Yellow Card scheme.

The correct starting point for anyone curious about the full schedule is our semaglutide dosage chart guide, which covers every licensed step with the clinical reasoning behind each one.

Why the dose ladder is shaped the way it is

A question our prescribers field most weeks is why Wegovy starts so low. At 0.25mg the body is adjusting to a mechanism it has not experienced before, gastric emptying slows, appetite signals shift, and the gut can react strongly. Beginning gently is not a clinical nicety; it is how the medicine was tested and licensed, and it is how most people avoid the worst of the early nausea.

Each four-week hold gives the prescriber a window to check how you are tolerating the current strength before moving up. Some people stay at 1.7mg if 2.4mg causes side effects that outweigh the benefit. Others, with the 7.2mg pen now available, may continue upward. The prescriber reads both your weight response and your experience of the medicine, then decides. Dose timing is personal, not automatic, which is why a chart, on its own, is a guide rather than a plan.

For a side-by-side look at how Wegovy's doses compare in practice, our Wegovy doses page walks through each step with plain-language context.

What 10mg semaglutide searches usually mean, and what to do instead

It is worth pausing on why this search happens at all. Some people arrive at "10mg semaglutide" because they have seen it on a social-media post, because a private clinic quoted them a dose in different units (milligrams per millilitre, for instance), or because content written for a US audience has mixed in differently numbered compounded formulations. The unit confusion is real: a 5mg/mL concentration in a vial, drawn into a syringe, can produce doses that look unfamiliar on a standard Wegovy chart. Our guide to 5mg/mL semaglutide dosage charts addresses that specific format for anyone navigating it.

If you are thinking about semaglutide for weight management, the right starting point is a clinical assessment, not a chart search. A prescriber will confirm which product is appropriate, which starting dose suits your health profile, and how quickly or slowly to move through the schedule. There is no shortcut that replaces that conversation, and no chart that substitutes for it. Payday arrives, a new week starts, the calendar lines up, whatever your moment is, the process begins with a consultation, not a dosage number.

For context on what private semaglutide treatment typically costs and what a transparent price should include, the Wegovy price page is a useful read before you proceed. And if you want to understand the broader treatment landscape, including how semaglutide compares to other options, our weight-loss treatments overview covers the full picture.

What the evidence says about semaglutide's licensed doses

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks on 2.4mg semaglutide weekly alongside lifestyle support. Average weight reduction in that trial was around 15%. Those results applied to the licensed dose and schedule, not to higher unlicensed amounts, and not to any compounded version. More recently, trials at the 7.2mg dose reported around 20.7% average weight loss over 72 weeks, approaching outcomes seen with tirzepatide at its highest doses. You can read more about how higher concentrations fit into the treatment picture on our 30 mg semaglutide page, which sets out what that format is, where it comes from, and why it sits outside the licensed UK supply chain.

These figures come from tightly controlled settings with consistent dosing, clinical oversight, and verified supply chains. Real-world results vary, and no treatment guarantees any particular outcome. What the data does tell us is that the licensed doses work well enough that adding unlicensed alternatives carries risk with no proven benefit.

NICE's appraisal of semaglutide for weight management (TA875) outlines both the evidence base and the clinical criteria that guide prescribing. Reading it alongside the NHS medicines page gives a clear sense of what regulated semaglutide treatment is and is not.

If you have questions about which treatment might suit your situation, our clinical team reviews every consultation personally. Start your free consultation and a GPhC-registered prescriber will assess your case the same day.